Literature DB >> 12153511

The ability of antigen, but not interleukin-2, to promote n-butyrate-induced T helper 1 cell anergy is associated with increased expression and altered association patterns of cyclin-dependent kinase inhibitors.

Stephanie K Jackson1, Annick DeLoose, Kathleen M Gilbert.   

Abstract

The ability of the cell cycle inhibitor n-butyrate to induce T helper 1 (Th1) cell anergy is dependent upon its ability to block the cell cycle progression of activated Th1 cells in G1. Results reported here show that although both interleukin (IL)-2 and antigen (Ag) push Th1 cells into G1 where they are blocked by n-butyrate, only the Ag-activated Th1 cells demonstrate functional anergy once the n-butyrate has been removed from the culture. Because n-butyrate-induced Th1 cell anergy has been linked to increased expression of the cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1, mechanistic experiments focused on the role of these inhibitors. It was found that when Th1 cells were reincubated in Ag-stimulated secondary cultures, the Th1 cells previously exposed to Ag and n-butyrate (anergic Th1 cells) demonstrated a cumulative increase in p21Cip1 and p27Kip1 when compared with Th1 cells previously exposed to recombinant (r)IL-2 and n-butyrate (non-anergic Th1 cells). p27Kip1 in the anergic Th1 cells from the secondary cultures was associated with cyclin-dependent kinases (cdks). In contrast, p21Cip1 in the anergic Th1 cells, although present at high levels, did not associate significantly with cdks, suggesting that p21Cip1 may target some other protein in the anergic Th1 cells. Taken together, these findings suggest that Th1 cell exposure to Ag and n-butyrate, rather than IL-2 and n-butyrate, is needed to induce the cumulative increase in p21Cip1 and p27Kip1 that is associated with the proliferative unresponsiveness in anergic Th1 cells. In addition, p21Cip1 may inhibit proliferation in the anergic Th1 cells by some mechanism other than suppression of cdks that is unique to the induction of Th1 cell anergy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153511      PMCID: PMC1782758          DOI: 10.1046/j.1365-2567.2002.01457.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  A non-enzymatic p21 protein inhibitor of stress-activated protein kinases.

Authors:  J Shim; H Lee; J Park; H Kim; E J Choi
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

2.  Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness.

Authors:  H Quill; R H Schwartz
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

3.  Cyclin E-CDK2 is a regulator of p27Kip1.

Authors:  R J Sheaff; M Groudine; M Gordon; J M Roberts; B E Clurman
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

4.  Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner.

Authors:  H Xiao; T Hasegawa; O Miyaishi; K Ohkusu; K i Isobe
Journal:  Biochem Biophys Res Commun       Date:  1997-08-18       Impact factor: 3.575

5.  Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.

Authors:  J Nourse; E Firpo; W M Flanagan; S Coats; K Polyak; M H Lee; J Massague; G R Crabtree; J M Roberts
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

6.  p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells.

Authors:  S Y Archer; S Meng; A Shei; R A Hodin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

7.  Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones.

Authors:  M K Jenkins; D M Pardoll; J Mizuguchi; T M Chused; R H Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists.

Authors:  J Madrenas; R H Schwartz; R N Germain
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA.

Authors:  J Chen; P K Jackson; M W Kirschner; A Dutta
Journal:  Nature       Date:  1995-03-23       Impact factor: 49.962

10.  Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.

Authors:  O Aprelikova; Y Xiong; E T Liu
Journal:  J Biol Chem       Date:  1995-08-04       Impact factor: 5.157

View more
  4 in total

Review 1.  Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

Authors:  Andrew D Wells
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

2.  p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(+) T-cell anergy selectively associates with mitogen-activated protein kinases.

Authors:  Ayse Selma Dagtas; Kathleen M Gilbert
Journal:  Immunology       Date:  2009-09-11       Impact factor: 7.397

3.  Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.

Authors:  Paolo Antonio Ascierto; Caroline Robert; Clélia Coutzac; Jean-Mehdi Jouniaux; Angelo Paci; Julien Schmidt; Domenico Mallardo; Atmane Seck; Vahe Asvatourian; Lydie Cassard; Patrick Saulnier; Ludovic Lacroix; Paul-Louis Woerther; Aurore Vozy; Marie Naigeon; Laetitia Nebot-Bral; Mélanie Desbois; Ester Simeone; Christine Mateus; Lisa Boselli; Jonathan Grivel; Emilie Soularue; Patricia Lepage; Franck Carbonnel; Nathalie Chaput
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

4.  HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.

Authors:  Tamson V Moore; Gina M Scurti; Matthew DeJong; Siao-Yi Wang; Annika V Dalheim; Courtney R Wagner; Kelli A Hutchens; Jodi J Speiser; Constantine V Godellas; Chris Fountain; Jessica Fleser; Tarsem Moudgil; Mallory Thomas; David Murray; Brendan D Curti; Joseph I Clark; Bernard A Fox; Michael I Nishimura
Journal:  Mol Ther Oncolytics       Date:  2021-01-26       Impact factor: 7.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.